8/8/2023 0 Comments Daniel schwartzBecause Caltech does not have a medical school, there is often an important practical knowledge-gap among its researchers about important unsolved problems in the clinic likewise, leading academic clinicians are generally unaware of newly emerging basic discoveries and technologies that could be leveraged to enhance clinical care. Their start-up, NVasc, has demonstrated proof of concept in animal models and is currently embarking on the pre-clinical studies required to initiate clinical trials.īroadly, Dan's work with Caltech can be seen as an academic physician leveraging the world class science and engineering at Caltech to solve problems he has confronted over his career in ophthalmic care. More recently, Dan and Bob Grubbs have established a collaboration with Lasker Award winner, Napoleone Ferrara, MD (UCSD), to develop a new class of pharmaceutical agents to treat retinovascular disease. This is a very challenging project, but they are developing a prototype device which could be inserted just like an intraocular lens that could restore vision in these patients who are blind from severe bilateral corneal scarring. This technology is now widely used internationally in the care of patients with macular degeneration, diabetic retinopathy, and other retinovascular diseases.ĭan has also worked Mory Gharib (Aeronautics and Bioinspired Engineering) and David Jeon, PhD to treat corneal blindness, one of the most common causes of blindness in under-developed countries. With Scott Fraser (now at USC), Bob Grubbs, and post-doc Jeff Fingler, Dan collaborated to develop optical coherence tomography angiography (OCTA), the first non-invasive means of imaging the retinal vasculature. The LAL is now FDA approved and is being commercialized by RxSight () in the US. This enables patients to have optimal vision after cataract surgery without the use of spectacles. With Bob Grubbs (Chemistry), Julie Kornfield (Chemical Engineering), and post-docs Chris Sandstedt and Jagdish Jethmalani, Dan collaborated to develop the Light Adjustable Lens (LAL), the first intraocular lens for cataract surgery that can be adjusted non-invasively using light. Over the past 25 years, Dan has collaborated with several faculty at Caltech working to develop various medical devices and more recently, therapeutic agents. For the past 30 years he has been on the full-time faculty at USCF where he held the Shirley Reich Chair in Ophthalmology and directed the Retina Division at both UCSF and the San Francisco VA Medical Center. He then received specialty training in vitreoretinal surgery, medical retina, and ultrasound. Dan will also be working with Caltech MD-PhDs, postdocs, grad students, and undergrads to help them explore and establish their own translational career paths.ĭan completed medical school at UCSF, followed by a residency in Ophthalmology at the Wilmer Eye Institute, Johns Hopkins Hospital. Dan is actively expanding a Caltech/UCSF Innovation Collaboration program that he originated with Caltech Chemistry Professor Bob Grubbs, in which Caltech researchers pair with leading clinicians at UCSF to identify and solve high-value translational problems. Dan's charge as the Institute's founding Physician in Residence is to promote and support translational research and education from his perspective as an academic clinician and an active translational researcher. Dan Schwartz was appointed as Physician in Residence of the Merkin Institute for Translational Research on July 1, 2020.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |